NPS Pharmaceuticals (NPSP) Stock Price, News & Analysis

Company Overview

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NPSP Stock Analysis - Frequently Asked Questions

How were NPS Pharmaceuticals' earnings last quarter?

NPS Pharmaceuticals Inc (NASDAQ:NPSP) released its earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.08. The biopharmaceutical company earned $66.70 million during the quarter, compared to the consensus estimate of $69.30 million.

What other stocks do shareholders of NPS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NPS Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), GE Aerospace (GE), Intercept Pharmaceuticals (ICPT), Meta Platforms (META), Pharmacyclics (PCYC) and Pfizer (PFE).

Company Calendar

• Last Earnings: 2/18/2015
• Today: 8/25/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NPSP
• CIK: 890465
• Web: www.npsp.com
• Phone: +1-908-4505300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A